Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1)

Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two Phase 1 studies in patients with advanced or metastatic solid tumors, including patients with active CNS disease. Here we summarize the overall safety and report the antitumor activity of entre...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Discov
Main Authors: Drilon, Alexander, Siena, Salvatore, Ou, Sai-Hong Ignatius, Patel, Manish, Ahn, Myung Ju, Lee, Jeeyun, Bauer, Todd M., Farago, Anna F., Wheler, Jennifer J., Liu, Stephen V., Doebele, Robert, Giannetta, Laura, Cerea, Giulio, Marrapese, Giovanna, Schirru, Michele, Amatu, Alessio, Bencardino, Katia, Palmeri, Laura, Sartore-Bianchi, Andrea, Vanzulli, Angelo, Cresta, Sara, Damian, Silvia, Duca, Matteo, Ardini, Elena, Li, Gang, Christiansen, Jason, Kowalski, Karey, Johnson, Ann, Patel, Rupal, Luo, David, Chow-Maneval, Edna, Hornby, Zachary, Multani, Pratik S., Shaw, Alice T., De Braud, Filippo G.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2017
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380583/
https://ncbi.nlm.nih.gov/pubmed/28183697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1237
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים